It took me weeks to come to terms with the fact that there were no easy answers. I couldn't change the past or the diagnosis, so I focused on educating myself and becoming Tinslee's biggest advocate. We underwent all the necessary tests, scans, and procedures, and spent a year going in for lab work and check-ups.
Directory
![](https://fanconi.org/wp-content/uploads/2018/04/Peter_Kurre.png)
Peter Kurre
Director of the Pediatric Comprehensive Bone Marrow Failure Center | MD | Philadelphia, USA
With extended training in pediatric hematology, oncology and stem cell transplantation, Dr. Kurre’s clinical work is focused on children with hematopoiesis failure (i.e., bone marrow failure) across a wide spectrum of inherited and acquired conditions that lead to loss of blood formation. As a physician-scientist, his clinical and scientific goals are directed at improving our understanding and broadening our treatment options for patients with bone marrow failure.
Dr. Kurre’s clinical interests focus on diagnosis and treatment of bone marrow failure, specifically on improving diagnostic and therapeutic capabilities. Along with colleagues at other institutions, he is spearheading efforts to leverage molecular technologies toward the development of tests that improve diagnostic certainty and timeliness of genetic hematopoiesis failure conditions. Dr. Kurre’s laboratory has longstanding expertise in Fanconi anemia (FA), a rare inherited genetic condition with prominent hematologic complications. The long-term goal is to improve our understanding of the progressive hematopoietic failure that occurs in patients with FA. His other lab projects are focused on stem cell regulation by trafficking of extracellular vesicles in the bone marrow microenvironment.
FA Research Projects
The Latest
News & Events
![](https://fanconi.org/wp-content/uploads/2024/07/Tinslee-1024x683.jpeg)
![](https://fanconi.org/wp-content/uploads/2024/07/Isis-scaled-e1721144755695-1024x987.jpg)
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.
![](https://fanconi.org/wp-content/uploads/2024/07/PXL_20240524_145121333-1024x771.jpg)
On May 24th, 2024, the FA Europe Network hosted its inaugural pan-European scientific meeting at the historic Saint-Louis Hospital in Paris, marking a significant milestone in international collaboration for Fanconi anemia (FA).